Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02500407 · ClinicalTrials.gov registry record · Phase 1
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 713
- Enrollment target
NCT02500407: Completed Phase 1 study, sponsored by Genentech.
NCT02500407 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 713 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1088% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02500407, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 713 participants
- Enrollment target
Study Summary
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Interventions
- DRUG Atezolizumab
- DRUG BTCT4465A (Mosunetuzumab) IV
- DRUG BTCT4465A (Mosunetuzumab) SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 713 participants |
| Start Date | 2015-09-15 |
| Est. Completion | 2025-09-01 |
| Phase | Phase 1 |
What the finished NCT02500407 record still lists
NCT02500407 is an interventional study that assigns participants to a tested intervention. The registered 713 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1088% higher).
The record links to 0 conditions, and to 3 interventions - of which Atezolizumab is the first listed.
NCT02500407 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02500407 about?
NCT02500407 is a clinical study titled "A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)". This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will ...
What is the current status of trial NCT02500407?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 713 participants. The study started on 2015-09-15. Estimated completion is 2025-09-01.
What interventions are being tested in trial NCT02500407?
The interventions under investigation include: Atezolizumab (DRUG), BTCT4465A (Mosunetuzumab) IV (DRUG), BTCT4465A (Mosunetuzumab) SC (DRUG).
Who is sponsoring clinical trial NCT02500407?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02500407's enrollment target sits among peer trials
713 19th of 2000 higher than 1,982 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NCT06758401 · 714 participants · Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- NCT04680000 · 716 participants · NA
Chronic Pain Management In Primary Care Using Behavioral Health Consultants
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI